Kornimate/medical-research-clean huggingface dataset:
efficacy of tart cherry juice in reducing muscle injury and biomarkers of muscle damage among healthy adults

Conditions: Inflammation; Pain

Summary: the purpose of this study is to assess the effects of tart cherry juice to reduce serum biomarkers of inflammation and reduce muscle soreness in healthy adults who undergo a bout of controlled eccentric exercise.

numerous antioxidant and anti-inflammatory agents have been identified in tart cherries, and a study among healthy, non-exercising individuals demonstrated that tart cherries decreased post-exercise weakness and muscle pain. the purpose of this study is to assess the analgesic and myoprotective effects of tart cherry juice among healthy subjects in a randomized, placebo controlled, double-blind, crossover design trial. fifteen healthy individuals will perform a bout of eccentric elbow flexion contractions (2 x 10 near maximum), and will then ingest 10 fl oz of a cherry juice or a placebo juice twice a day for four days, beginning immediately post exercise. before and after exercise, and for three days following the eccentric exercise, blood will be drawn to measure serum biomarkers of muscle damage and muscle soreness will be recorded. the protocol will be repeated after a 9-10 day washout period with subjects consuming the alternative juice for the second trial. the opposite arm will perform the eccentric exercise for the second bout to avoid the repeated bout protective effect. the study's outcomes are 1) to assess changes in serum biomarkers of muscle damage, and 2) to assess changes in muscle soreness.

Eligibility criteria:
inclusion criteria: * no regular upper body strength training * no elbow flexor pain, no history of elbow or shoulder injury * ability and willingness not to take any anti-inflammatory or pain relieving drugs during the course of the study, not to seek any other treatment for any symptoms of muscle damage directly resulting from the exercises performed as part of the study, and not to exercise their upper extremities during the study. exclusion criteria: * individuals who have used or are using antiepileptic drugs for pain, acupuncture, or transcutaneous electrical nerve stimulation within 3 weeks before enrollment * recent use (within 5 half-lives) of topical medications/anesthetics, muscle relaxants, tender point anesthetic injections within 2 months * systemic steroid use within 3 months * any investigational drug/device use in the prior 30 days * individuals who have type 1 or type 2 diabetes * individuals who are pregnant

Keywords: pain inflammation muscle damage
pre pectoral implant for immediate breast reconstruction using single port endoscopy in prophylactic indication

Conditions: Genetic Predisposition; Breast Cancer

Summary: implant-based reconstruction is currently the most common choice for mastectomy reconstruction. whatever the choice of mastectomy incision, a scar remains on or near the breast volume. current techniques involve partial or total coverage of the implant with the pectoralis major muscle, to prevent exposure or infection. the muscle dissection technique applied has functional and cosmetic consequences. in this study, an endoscopic approach will be evaluated. this new surgical technique, using a single-port endoscopic way, will put the scar is in the axillary area, away from the breast. the hypothesis is that this delocalized scar potentially reduces the risk of exposure and allows placement of the implant in the subcutaneous space, with no manipulation of the pectoralis major muscle.

it s a practicability study, evaluating endoscopic approach for prophylactic mastectomy, using an axillary single port. classic open surgery conversion rate, operative time, infectious rate, esthetical outcomes, and functional outcomes will be evaluated.

Eligibility criteria:
inclusion criteria: * patient with an indication for prophylactic uni or bilateral mastectomy (genetic risk factors for breast cancer) * ask an immediate breast reconstruction during the surgery * world heath organization score \<3 * glandular volume : french bra cup size a, b ou c * glandular ptosis \<=2 (classification and algorithm for treatment of breast ptosis) * contraception for woman of childbearing age and no pregnancy * valid social security * wrote consent exclusion criteria: * history of breast cancer surgery * breast cancer not operated on the side concerned by the prophylactic mastectomy * patient having had irradiant treatment * breast hypertrophy * smoking \> 10 cigarette/day * body mass index \> 30 * large breast volume requiring prostheses \> 500ml * chronic pulmonary obstructive gold 4 * asa (physical status score of american society of anesthesiologists) \> 3 * chronic shoulder pain on the side to operate, or both shoulders * history of abarticular pathology of the shoulder on the operating side * patient involvment in another clinical research * protected patient or unable to give consent * pregnant or breastfeeding woman * vulnerable person (article l1121-6 of the public health code)

Keywords: prophylactic surgical procedure subcutaneous mastectomy endoscopy breast reconstruction breast implants
identification of new serum markers for detection of abuse with erythropoietin

Conditions: Substance Abuse Problem

Summary: epo increases red blood cell production and hence the amount of oxygen that can be transported around the body. it is shown that prolonged use of synthetic epo (rhuepo) leads to an increase in the period of time a given physical work can be performed, therefore it will continue to be abused by athletes, especially in endurance sports. the existing method for measuring the abuse of rhuepo approved by the world anti-doping agency (wada) is based on differences in the sugar groups bound to rhuepo and epo produced in the body, respectively. proteomics is a method by which one can look at all the proteins in blood at the same time. even proteins that have changed very little can be distinguished. the main objective of this project is to investigate the effect of prolonged treatment with rhuepo on changes in blood proteins in healthy young men.


Eligibility criteria:
inclusion criteria: * healthy men * age 18-35 * untrained * bmi: 20-25 exclusion criteria: * smokers * chronic diseases * malignancy (former or present) * alcohol, drug or epo abuse

Keywords: epo proteomics carbohydrate metabolism fat metabolism protein metabolism
intraoperative berger space imaging (ibsi)

Conditions: Cataract; Macula Edema

Summary: the investigational device is an approved femtosecond laser (fsl) device with an integrated imaging system to perform certain steps of the cataract procedure. the fsl will perform anterior capsulotomy and lens fragmentation in individuals suffering from age-related cataract with need of cataract surgery. the laser will be reduced to image the berger space. if not visible, the space will be enhanced with bss and volon a to visualize the bs. cataract surgery will be performed in subjects who have signed an informed consent form. macula thickness will be measured with spectralis oct on screening date. postoperative examinations will be implemented in accordance with the approved investigational plan on subjects and includes: visual acuity, slitlamp examination and retinal oct imaging.


Eligibility criteria:
inclusion criteria: * bilateral age-related cataract necessitating phacoemulsification extraction and posterior iol implantation * age: 40 to 90 (females of childbearing age will be interviewed if pregnancy is possible) * preoperative pupil size in mydriasis ≥ 6.0 mm exclusion criteria: * preceding ocular surgery or trauma * pseudoexfoliation * recurrent intraocular inflammation of unknown etiology * uncontrolled glaucoma * uncontrolled systemic or ocular disease * blind fellow eye * microphthalmus * corneal abnormality * history of uveitis/iritis * iris neovascularization * proliferative diabetic retinopathy * macular degeneration or any other relevant macular diseases * pregnancy
velocity time integral vs picco for evaluation of passive leg raising in septic shock

Conditions: Septic Shock

Summary: the objective of the present study is to investigate accuracy of changes in cardiac output following passive leg raising as estimated by transthoracic ultrasound as method to predict fluid responsiveness and compare that to changes in cardiac output following plr as estimated by calibrated pulse contour analysis as method to predict fluid responsiveness in patients with septic shock.

one method to predict fluid responsiveness is to increase preload by transferring blood from the lower extremities to the central compartment through a passive leg raising (plr) maneuver and then measure the resulting change in cardiac output. it was recently suggested that an increase in cardiac output following plr had a high accuracy compared other methods to test fluid responsiveness. different methods to estimate change in cardiac output have been used in studies investigating accuracy of plr. most commonly calibrated pulse contour analysis has been used in mechanically ventilated patients whereas transthoracic echocardiography (tte)has been used in spontaneously breathing patients. while tte offers the advantage of being less invasive than calibrated pulse contour analysis it is technically challenging and user dependent and the accuracy of the two methods has not been compared.

Eligibility criteria:
inclusion criteria: 1. septic shock according to the sepsis-3 criteria 2. the treating physician plans to administer fluid to improve organ perfusion and oxygenation due to signs of inadequate organ perfusion and hypoxia (skin mottling, tachycardia (\>100), urine output below 0.5 ml/kg/h, lactate persistently \> 2 mmol/l and central venous oxygen saturation \ 65 mmhg. 3. hemodynamic monitoring with transpulmonary thermodilution initiated as part of routine clinical monitoring. exclusion criteria: 1. any condition that will affect the reliability of the plr procedure or is a contraindication to plr (compression stockings or intraabdominal pressure \> 12 mm hg, raised intracranial pressure). 2. pao2/fio2 \< 100 mmhg (13.3 kpa) or suspicion of cardiogenic edema 3. transthoracic echo does not allow recording of vti. 4. age \>18 years. 5. no informed consent 6. prior inclusion in the study

Keywords: passive leg raising fluid responsiveness pulse contour analysis transthoracic ultrasound velocity time integral
trial to evaluate ultrasound in the treatment of tibial fractures

Conditions: Tibial Fractures

Summary: the purpose of this study is to determine the effect of low-intensity, pulsed ultrasound on tibial fractures treated with intramedullary nailing.

a randomized, placebo controlled, clinical trial to evaluate the safety and efficacy of low-intensity, pulsed ultrasound, applied to tibial fractures treated with intramedullary nailing.

Eligibility criteria:
inclusion criteria: * males and females age 18 years or older * have an open or closed tibial fracture amenable to intramedullary nail fixation exclusion criteria: * tibial fracture associated with a vascular injury requiring repair * pilon fractures * tibial fractures that extend into the joint and require reduction * pathologic fractures • bilateral tibial fractures

Keywords: tibia
whole-body hyperthermia for moderate to severe depressive disorder

Conditions: Depression, Unipolar

Summary: the primary aim of this study is to investigate the effectiveness of whole-body hyperthermia in addition to standard medical care in comparison to standard medical care alone on depressive symptom severity in patients with moderate to severe depressive disorder. secondary aims included further quality of life outcomes, immunological parameters, and tolerability/safety of the hyperthermia.


Eligibility criteria:
inclusion criteria: * unipolar depression (diagnosed according to the dsm-iv) * moderate depression: 17-23 points on the hamd-17 or severe depression: ≥24 points on the hamd-17 exclusion criteria: * participants who did not respond to prior antidepressant drug treatment, electroconvulsive therapy, or sleep deprivation (therapy-resistant depression) * acute suicidality * prior treatment with whole-body hyperthermia * contraindications to hyperthermia treatment: acute or feverish infections, severe cardiovascular diseases (e.g. angina pectoris, heart failure, thrombosis, bleeding diathesis), severe gastrointestinal diseases (e.g. renal insufficiency, hepatitis, liver cirrhosis, peptic ulcer), severe neurological diseases (e.g. epilepsy, multiple sclerosis, cerebrovascular malformations or brain tumors), severe endocrine diseases (e.g. hyperthyroidism), or oncological diseases without remission * participants taking anti-inflammatory or immunosuppressive drugs * participants with severe psychiatric comorbidities (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, dementia, adhd, obsessive-compulsive disorder, ptsd, alcohol or drug addiction) * women during pregnancy and breastfeeding * lack of ability to consent

Keywords: depression hyperthermia randomized controlled trial
ziprasidone for improving insulin sensitivity in people with schizophrenia who are at risk for diabetes

Conditions: Schizophrenia; Metabolic Syndrome X; Insulin Resistance

Summary: this study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes.

people with schizophrenia often lead more sedentary lifestyles than people without the disease, and they are frequently treated with antipsychotic medications that cause weight gain. combined, these factors produce an increased risk for metabolic syndrome, which can lead to heart disease and type 2 diabetes. characteristics of metabolic syndrome include carrying excess weight around the abdominal region; high blood pressure; high blood sugar levels; high levels of fat in the blood; and low levels of hdl cholesterol. recent studies have shown that certain atypical antipsychotic drugs are relatively weight-neutral. switching from a drug that promotes weight gain to a weight-neutral medication, such as ziprasidone, may result in significant weight loss. there is insufficient evidence, however, demonstrating the extent of improvement in insulin sensitivity after switching medications. this study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes. participants in this open label study will currently be undergoing treatment with risperidone or olanzapine at the time of study entry. upon study entry, they will be randomly assigned to either switch to ziprasidone treatment or remain on their current medications. both groups will be treated for 26 weeks. participants will report to the study site for evaluations biweekly until week 10 and then monthly for the duration of the study. the primary outcomes at week 26 will be: change from baseline in insulin sensitivity, using an intravenous glucose tolerance test; change from baseline in ivisceral fat mass, using a ct scan.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder * currently receiving antipsychotic therapy with risperidone or olanzapine * overweight exclusion criteria: * diagnosis of diabetes * hospitalization for schizophrenia or schizoaffective disorder within 90 days prior to study entry * refractory schizophrenia or schizoaffective disorder * currently receiving therapy with clozapine * no stable residence and phone number for 90 days prior to study entry * prior unsuccessful treatment with ziprasidone * intolerance to ziprasidone

Keywords: ziprasidone olanzapine risperidone schizoaffective disorder insulin sensitivity visceral adiposity metabolic syndrome
safety and efficacy study of imexon for treatment of multiple myeloma patients

Conditions: Multiple Myeloma

Summary: amp-007 is a phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. the first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. the phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether imexon can improve the outcome for patients with multiple myeloma


Eligibility criteria:
inclusion criteria: * advanced myeloma, with measurable disease as defined in the protocol. * prior treatment, at least 2 prior regimens are required. this may include prior treatment with investigational products. * able to perform the activities of daily living. * off prior therapy for at least 2-4 weeks depending on the drug. * blood counts and blood chemistries in or near normal range. * if female, neither pregnant nor nursing. * willing to use contraceptives to prevent pregnancy. * no other serious illnesses. * no other active malignancy. * no serious infections. * no current other drug therapy for the myeloma except for steroid therapy under certain circumstances. biphosphonate therapy is permitted. * prior radiation is permitted. exclusion criteria: * use of corticosteroids for amyloid disorders, or high dose chronic steroids.
inhaled fentanyl citrate & dyspnea

Conditions: Dyspnea

Summary: "dyspnea" refers to the awareness of breathing discomfort that is typically experienced during exercise in health and disease. in various participant populations, dyspnea is a predictor of disability and death; and contributes to exercise intolerance and an adverse health-related quality-of-life. it follows that alleviating dyspnea and improving exercise tolerance are among the principal goals of disease management. nevertheless, the effective management of dyspnea and activity-limitation remains an elusive goal for many healthcare providers and current strategies aimed at reversing the underlying chronic disease are only partially successful in this regard. thus, research aimed at identifying dyspnea-specific medications to complement existing therapies for the management of exertional symptoms is timely and clinically relevant. the purpose of this study is to test the hypothesis that single-dose inhalation of fentanyl citrate (a mu-opioid receptor antagonist) will improve the perception of dyspnea during strenuous exercise in healthy, young men in the presence of an external thoracic restriction. to this end, the investigators plan compare the effects of inhaled 0.9% saline placebo and inhaled fentanyl citrate (250 mcg) on detailed assessments of neural respiratory drive (diaphragm emg), ventilation, breathing pattern, dynamic operating lung volumes, contractile respiratory muscle function, cardio-metabolic function and dyspnea (sensory intensity and affective responses) during symptom-limited, high-intensity, constant-work-rate cycle exercise testing with and without external thoracic restriction in healthy, men aged 20-40 years.


Eligibility criteria:
inclusion criteria: * male * aged 20-40 years * fev1 ≥80% predicted * fev1/fvc \>70% exclusion criteria: * current or ex-smoker * body mass index \ 30 kg/m2 * history of cardiovascular, vascular, respiratory, renal, liver, musculoskeletal, endocrine, neuromuscular and/or metabolic disease/dysfunction * taking doctor prescribed medications * history of using pain-relieving (opioid) and/or anti-depressant medications in the previous 6 weeks * allergy to latex * allergy to lidocaine or its "caine" derivatives

Keywords: fentanyl citrate opioids exercise
prophylaxis of venous thromboembolism in advanced lung cancer

Conditions: Lung Cancer

Summary: to compare the efficacy and safety of prophylaxis of venous thromboembolism by nadroparin during hospitalization to long-term usage in patients with advanced lung cancer treated by chemotherapy and/or radiotherapy.

this is a prospective, multi-center, randomized and controlled study. advanced lung cancer patients without venous thromboembolism(vte) are included. the selected patients were randomized into a and b groups. group a: nadroparin given during hospitalization, 0.4ml, subcutaneously, qid; group b: nadroparin given by long-term, 0.4ml, subcutaneously, qid. the incidence of vte , the risks of bleeding and overall survival in two groups of patients are studied at different time points.

Eligibility criteria:
inclusion criteria: * stage ⅲ b and ⅳ non-small cell lung cancer patients and inoperable small cell lung cancer patients * performance status score ≤ 2 * chest ct with measurable lesions exclusion criteria: * examination revealed any part of venous thromboembolism * chemotherapy regimens containing bevacizumab or endostar * severe coagulopathy * active bleeding within two weeks

Keywords: nadroparin venous thromboembolism prophylaxis
peritoneal lavage for early detecting gene mutation of peritoneal metastasis of gastric cancer

Conditions: Gastric Cancer

Summary: our study aims to improve sensitivity and accuracy of detecting abdominal free cancer cells in patients with gastric cancer.

gastric cancer (gc) remains one of the most common causes of cancer-related mortality worldwide. surgery has always been considered as the most effective treatment for gc. peritoneal metastasis is the common pattern of postoperative recurrence, especially patients with t4 stage or serosal invasion. what is worse, patients with peritoneal metastasis have a poor prognosis. however, it is often difficult to diagnose peritoneal metastasis at an early stage. as we know, the implantation of peritoneal free cancer cells exfoliating from serosa-invasive tumors is main reason of peritoneal seeding. cytological examination of peritoneal lavage fluid is always performed to predict peritoneal micrometastases. however, more than half of patients with negative cytological results develop peritoneal recurrence. low sensitivity and poor negative predictive value of this method have heralded the development of advanced techniques in detecting peritoneal free cancer cells. in this study, novel genetic techniques will be used to detect mutated dna of shed cancer cells in abdominal cavity. the present clinical trial aims to find a better tool to detect abdominal micrometastasis in gc patients, which may become a valid clinical index to predict postoperative relapse and direct treatment.

Eligibility criteria:
inclusion criteria: 1. lower age limit of research subjects 18 years old and upper age limit of 80 years old. 2. ps (ecog) of 0 or 1 and expected to survive more than 6 months. 3. written informed consent from the patient. 4. patients suffering gastric cancer and non-cancerous disease planned to have laparotomy. exclusion criteria: 1. female in pregnancy or lactation. 2. patients participating in any other clinical trials currently，or participated in other trails within 1 months. 3. patients with poor compliance or considered to be poor compliance. -

Keywords: peritoneal lavage, gene mutation, peritoneal metastasis,gastric cancer